UCB 4594
Alternative Names: Anti HLA-G antagonist; UCB-4594Latest Information Update: 31 Mar 2023
At a glance
- Originator UCB Biopharma
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; HLA-G antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Mar 2023 Cancer Research UK enters into agreement with UCB for clinical development of UCB 4594 in Cancer
- 09 Mar 2023 Cancer Research UK and UCB Biopharma plans a phase I/II trial for Solid tumour (Monotherapy, Combination therapy, Late-stage disease, Second-line therapy or greater) in United Kingdom in May 2024 (IV) (NCT06380816)
- 09 Mar 2023 Preclinical trials in Cancer in Belgium (Parenteral) before March 2023